What is your preferred second line therapy for patients with metastatic large cell neuroendocrine carcinoma of the lung after progression on first line chemo-immunotherapy?

Let's start by backtracking to the original treatment recommendation. Since large cell neuroendocrine carcinomas (LCNEC) of the lung can harbor mutations in EGFR or BRAF or even ALK rearrangements, next generation sequencing is appropriate for patients with advanced disease.

Assuming no targetable al...